Skip to main content

Table 3 Main Characteristics of the Analyzed Trials

From: R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature

Study Patient Population Treatment
(N)
CR
(n; %)
PR
(n; %)
OR
(n; %)
Criteria
Czuczman et al [4]: Prospective; Single treatment group; Intent to treat trial N-40; 18 years and older with CD 20+ follicular lymphoma R-CHOP
N = 40
22; 55% 16; 40% 38; 95% Table 1
Hiddemann W et al. [5]: Prospective, randomized, non-crossover, open label multicenter phase 3 trial N = 428; 18 years and older with untreated advanced stage follicular lymphoma R-CHOP
(N = 223)
vs.
CHOP
(N = 205)
44; 20%
35; 17%
170; 77%
150; 73%
214; 96%
185; 90%
IWG[13]
Domingo-Domenech et al. [6]: Prospective, non-randomized, non-crossover, open label multicenter phase 2 trial N = 16; 18 to 70 years age with CD 20+ follicular lymphoma R-CHOP
(N = 16)
12; 75% 2; 13% 14; 88% IWG [13]
Marcus R et al. [7]: Prospective, randomized, non-crossover trial N = 321; 18 years or older, untreated CD 20+ follicular lymphoma R-CVP
(N = 162)
vs.
CVP
(N = 159)
66; 41%
16; 11%
65; 40%
74; 47%
131; 81%
90; 57%
IWG[13]